A rare genetic disease can have different genetic causes in different patients, making a single treatment design an imperfect fit for everyone with that diagnosis. On October 27, federal health officials announced draft FDA guidance describing how related, personalized gene-editing therapies could share an approval application. The proposal is open for public comment and remains a draft, with nonbinding recommendations.

What happened

Reporting by the Regulatory Affairs Professionals Society describes a practical problem behind the proposal: treating every personalized version as a separate product can mean separate development programs and approval applications. At an FDA webinar, an agency official explained that the proposed approach would let developers put multiple versions into one BLA and add further versions after approval.

The FDA document addresses how applicants would describe the permitted differences between versions, as well as how they could add versions after a product is licensed. Its scope also covers laboratory evaluation of safety and potency, manufacturing validation, labeling, indications and product identification. Those are recommendations for developers preparing applications, with the final version still to come.

RAPS places this proposal within a series of FDA documents addressing individualized therapies and gene editing, including guidance on using prior knowledge across editing programs. The report also notes that the proposed scope concerns diseases caused by a single gene and versions intended to produce the same editing outcome. The shared application would therefore have scientific boundaries rather than simply grouping every treatment carrying a gene-editing label.

How it works, in plain English

Genome editing changes DNA at particular locations; it may happen inside the body or in cells removed, edited and returned to the patient. Patients with the same single-gene disease can have different harmful variants, so editing components may need to change to match the DNA target. Think of the proposed framework as a recipe with a defined list of allowed substitutions: the FDA calls that permitted range an individualized feature space.

HHS describes that feature space as predefined boundaries for how a product can differ between patients while remaining under one BLA. For an additional version within those boundaries, the framework could rely on earlier clinical evidence together with laboratory data rather than requiring another clinical trial for that version. Safety testing would still include the risk of unintended genetic changes.

The FDA draft says other features, such as strength, formulation and the delivery vehicle for products used inside the body, should remain constant across versions. The boundaries should have clinical support and explicit laboratory safety and activity criteria. In the recipe analogy, a substitution only qualifies when it stays inside the agreed rules and passes the relevant checks.

Clinical Supply Leader also identifies supply planning as an unresolved operational task: if more versions are added over time, teams must account for manufacturing needs and availability. The proposal therefore calls for coordination across quality, regulatory and manufacturing work as a program develops.

What we know, and what we don’t

Questions you could ask your doctor

• What is known about the specific genetic variant behind my diagnosis?
• Is there an established treatment or an appropriate research study for that variant?
• What evidence would you want before considering an individualized gene-editing treatment?

News and education only, not medical advice. Darwi explains published research and news for general education. It does not diagnose, treat or recommend any treatment. Talk to a licensed clinician about your own health. See our Medical Disclaimer and Editorial Policy. Corrections: admin@darwi.org.